Consideration of Comorbidities in Treatment Choice for Patients with Type 2 Diabetes (T2DM)

被引：0
作者：
Ritchey, Mary E.
Engel, Samuel S.
Liu, Zhiwen
Ntabadde, Catherine
Senderak, Michael
Shankar, Ravi
Qiu, Ying
Radican, Larry
Rajpathak, Swapnil
Brodovicz, Kimberly G.
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2513-PO
引用
收藏
页码：A636 / A636
页数：1
相关论文
共 50 条
  • [31] Development and Validation of Yoga Program for Patients with Type 2 Diabetes Mellitus (T2DM)
    Arun Thulasi
    Vinod Kumar
    Aarti Jagannathan
    Praveen Angadi
    Kundapur Umamaheswar
    Nagarathna Raghuram
    Journal of Religion and Health, 2022, 61 : 1951 - 1965
  • [32] Pioglitazone (PIO) enhances insulin sensitivity (IS) in patients with type 2 diabetes (T2DM)
    Johns, D
    Herz, M
    Tan, MH
    Robertson, KE
    Gonzalez, B
    Reviriego, J
    Grossman, LD
    DIABETES, 2002, 51 : A102 - A102
  • [33] Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI)
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A286 - A286
  • [34] ADHERENCE AND PERSISTENCE IN PATIENTS INITIATING TREATMENT WITH INJECTABLE THERAPIES FOR TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sicras-Mainar, A.
    Navarro, R.
    Ruiz, L.
    Morano, R.
    VALUE IN HEALTH, 2015, 18 (07) : A612 - A612
  • [35] Thrombogenicity of flowing blood is increased in patients with type 2 diabetes mellitus (T2DM) despite treatment with aspirin
    Natarajan, A
    Marshall, S
    Hanley, J
    Badimon, JJ
    Zaman, A
    HEART, 2005, 91 : A61 - A61
  • [36] Is Treatment of Nonalcoholic Steatohepatitis with Pioglitazone Equally Effective in Patients with Prediabetes Compared with Type 2 Diabetes (T2DM)?
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Hecht, Joan
    Tio, Fermin
    Cusi, Kenneth
    DIABETES, 2017, 66 : A64 - A64
  • [37] DELAYED TREATMENT MODIFICATIONS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH VERY POOR GLYCEMIC CONTROL
    Schwab, P.
    Saundankar, V
    Bouchard, J. R.
    Moretz, C.
    Baltz, J.
    VALUE IN HEALTH, 2014, 17 (03) : A264 - A264
  • [38] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [39] Real-World Treatment for Diabetic Nephropathy (DN) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Chaudhari, Paresh
    Zhou, Zhou
    Yang, Hongbo
    Zhao, Jing
    Wu, Eric
    Seifeldin, Raafat
    DIABETES, 2016, 65 : A603 - A603
  • [40] DIABETES Dapagliflozin-redefining treatment of T2DM?
    Chao, Edward C.
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (12) : 696 - 697
12345